The AAPS In Vitro Release and Dissolution (IVRD) Focus Group has now been put in place and approved by AAPS. The first meeting was held November 10,2004 ,at the AAPS Annual Meeting in Baltimore,MD,and 60 members were present. The mission of the focus group was reviewed and revised:
1. Explore new technologies/equipment for in vitro release testing of novel dosage forms 2. Provide a forum to discuss the specification-setting process 3. Identify current method development problems and the associated dosage forms-share solutions to these difficult problems 4. Explore the use of dissolution testing in applying the BCS/biowaivers 5. Explore in vitro release testing methods for dosage forms other than solid oral dosage forms 6. Discuss the calibration parameters of all official apparatus. 7. Explore how the test may be more relevant to the human physiology 8. Discuss validation principles for new and standard methods 9. Explore harmonization of ICH and Pharmacopeias 10. Evaluate statistics and modeling related to in vitro release and dissolution testing
The Chair and Chair-Elect were selected. Tahseen Mirza is now Chair,elected for a two-year term. The Chair-Elect is Edward Ciolkowski;he will succeed Tahseen Plans include a workshop given by the Focus Group Members since there are many worthy topics and many volunteers to speak. With the time remaining a lively discussion took place on several topics-validation for manual versus automation comparisons,validation for deaeration, use of dissolution testing as the content uniformity test, method transfer,and volume correction and media replacement.
Since this first meeting,there was a teleconference of the Steering Committee on January 20,2005. The plans to present an AAPS workshop on pertinent topics were discussed. A meeting of the focus group in April is in the planning stages.
For more information on the Focus Group,contact Tahseen Mirza at tahseen.mirza@pharma. novartis.com Tahseen Mirza and Edward Ciolkowski dx.doi.org/10.14227/DT120105P37
